Loading...

Alvotech

ALVOW•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$1.70
$0.20(13.33%)

Alvotech (ALVOW) Stock Overview

Explore Alvotech’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.5/100

Key Financials

Market Cap2.7B
P/E Ratio27.44
EPS (TTM)N/A
ROE-0.23%

AI Price Forecasts

1 Week$2.71
1 Month$2.05
3 Months$1.41
1 Year Target$4.35

ALVOW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Alvotech (ALVOW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $4.35.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 27.44 and a market capitalization of 2.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ALVOWStats details for ALVOW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ALVOWAnalyst Recommendations details for ALVOW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Alvotech Holdings SA, through its subsidiaries, develops and manufactures biosimilars for global markets. The company is based in Iceland.

CEO

Mr. Robert Wessman

Employees

1,012

Headquarters

Saemundargata 15-19, Luxembourg

Founded

2022

Frequently Asked Questions

;